|
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Clinical research trials and Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma. Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma clinical trial. Subjects frequently get the best healthcare possible for their Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma  Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
For Condition: stage 1 childhood lymphoblastic lymphoma,stage 1 childhood large cell lymphoma,stage 3 childhood large cell lymphoma,stage 4 childhood lymphoblastic lymphoma,stage 4 childhood large cell lymphoma,stage 3 childhood lymphoblastic lymphoma,stage 2 childhood large cell lymphoma,stage 2 childhood lymphoblastic lymphoma
Status: No longer recruiting
Sponsor(s): United Kingdom Children's Cancer Study Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating children who have newly diagnosed non-Hodgkin's lymphoma.
Details: OBJECTIVES: I. Determine whether event-free survival for children with T-cell non-Hodgkin's lymphoma (NHL) can be improved by the addition of a third intensification block at 35 weeks. II. Determine biology and treatment response of T-cell NHL and T-cell acute lymphocytic leukemia when both are treated with an identical leukemia type protocol and receive a third intensification block. III. Improve the outcome for the 25% of children who are not in remission at eight weeks by the addition of a block of sustained intensification before high dose methotrexate and continuing treatment. PROTOCOL OUTLINE: Patients receive induction therapy on days 1-28. Patients receive supportive oral prednisolone daily for three doses during weeks 1-4, vincristine IV weekly for 5 weeks starting on day 1, asparaginase intramuscularly or subcutaneously three times a week beginning on day 4, and methotrexate intrathecally on days 1 and 8. Patients who meet certain criteria are given first intensification therapy beginning on day 29. Patients receive three doses of oral prednisolone, vincristine IV on day 1, daunorubicin IV over 6 hours on days 1 and 2, etoposide IV over 4 hours on days 1-5, cytarabine IV every 12 hours by bolus injection on days 1-5, oral thioguanine daily on days 1-5, and methotrexate intrathecally as in induction therapy. Patients are followed at 8 weeks. Those patients who experience remission receive a third intensification block at 35 weeks. All patients receive three methotrexate infusions followed by continuation therapy beginning at week 14. As continuation therapy, patients receive oral mercaptopurine daily, oral methotrexate weekly, vincristine IV every 4 weeks, oral prednisolone for 5 days every 4 weeks, and intrathecal methotrexate every 12 weeks beginning at week 23 until 100 weeks from the start of treatment. Continuation therapy will be interrupted at about week 20 for the second intensification therapy. For second intensification therapy, patients receive oral prednisolone daily for 5 days, a single dose of vincristine on day 1, daunorubicin IV over 6 hours on days 1 and 2, etoposide IV over 4 hours on days 1-5, bolus injections of cytarabine every 12 hours on days 1-5, oral thioguanine daily on days 1-5, and intrathecal methotrexate as in induction therapy. Continuation therapy re-starts at week 23. Patients who receive the third intensification therapy will begin at week 35. For the third intensification therapy, patients receive three doses of oral dexamethasone, IV vincristine on day 1 of weeks 35-38, subcutaneous asparaginase for 9 days during weeks 35-38, intrathecal methotrexate on day 1 of weeks 35 and 39, IV cyclophosphamide on day 1 of weeks 39 and 41, subcutaneous or IV cytarabine daily on days 1-4 of weeks 39- 42, and oral thioguanine daily during weeks 39-42. Continuation therapy re-starts at week 42/43. Some patients may receive radiotherapy during chemotherapy. Patients are followed every month for 1 year, every 2 months for the next year, every 6 months for the next 3 years, then annually thereafter. PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study within 5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /14 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Newly diagnosed stage I, II, III, or IV T-cell non-Hodgkin's lymphoma - No T-cell large anaplastic, peripheral T-cell lymphomas, or T-cell lymphoblastic leukemia - No greater than 25% blasts in the bone marrow --Prior/Concurrent Therapy-- - No prior therapy --Patient Characteristics-- - Age: Under 15 - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JudithChessells, Study Chair, United Kingdom Children's Cancer Study Group
Hospital for Sick Children NHS Trust
London, England, WC1N 3JH
United Kingdom
Additional Information:
Study ID Numbers: CDR0000066443; UKCCSG-NHL-9503,EU-98012
Study Start Date: May 1995
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003423
Other Stage 4 Childhood Large Cell Lymphoma Studies:
1. Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
2. Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
3. Combination Chemotherapy in Treating Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma
Related Studies:
Other stage 4 childhood large cell lymphoma Clinical Trials
Other England Clinical Trials
Other London Clinical Trials
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
|
|
|
|
|
|
|
|
